obesity drugs glp-1 news today New research is challenging long-held assumptions about in weight loss treatments. A different approach may be emerging.⁠ ⁠ Click the link in bio to read the full story Weight loss drugs and addiction:

Tirzepatide and additional dual GLP-1/GIP receptor agonists that could eventually be developed in the future seem to be a promising furthest advance for the management of several cardiometabolic settings

Diabetics should not be competing for life-saving diabetes drugs with people looking to lose weight

While certain competitors may engage in price or generic competition, the sustainability of such leadership will only be achieved by players who have differentiated oral delivery systems, solid trial data, robust real-world evidence, wide distribution reach, and proper positioning in the obese care pathway

Trapp S, Cork SC

Bjorklund experienced: severe gastrointestinal events, and as a result sustained severe and permanent personal injuries, pain, suffering, and emotional distress, and incurred medical expenses